Question explored with the scientific record
Conversation so far
- 1 Was ozempic tested properly
- 2 What do studies show about risks like cancer, pancreatitis, and thyroid tumors?
Answered on this page ↓
What do studies show about risks like cancer, pancreatitis, and thyroid tumors?
The short version: the evidence on cancer, pancreatitis, and thyroid tumors from semaglutide is mixed, short-term, and mostly from manufacturer-funded trials that were not designed to find these harms.
The 2025 comprehensive review in the Journal of Clinical Investigation says overall cancer risk signals are neutral to slightly protective, but it also reports that findings on thyroid cancer are mixed, with some observational studies showing increased risk with earlier GLP-1 drugs and FDA warnings already in place [1]. For pancreatic cancer, the same review says results are inconsistent across studies, with some early FAERS signals but meta-analyses showing no excess risk or mixed results depending on the comparator [1]. The SUSTAIN 6 trial, which lasted only two years, found 1 case of pancreatic cancer on semaglutide versus 4 on placebo, and pancreatitis rates were similar (8 vs 10) [5]. That is too few events to conclude anything.
A 2025 retrospective study of 715 semaglutide users found that pretreatment screening for pancreatic and thyroid disease was almost never done: lipase, amylase, and calcitonin were not measured in any patient, and only 1.8% had a complete pre-treatment evaluation [2]. A case report from 2025 describes a patient who developed gallstone pancreatitis requiring emergency gallbladder removal while on semaglutide [3]. The evidence does not include a single long-term trial designed to track cancer or pancreatitis as a primary endpoint. The trials that exist were too short and too small to detect rare harms.
| Outcome | What the evidence shows | Trial duration |
|---|---|---|
| Pancreatic cancer | 1 vs 4 cases in SUSTAIN 6; meta-analyses mixed [1, 5] | 2 years |
| Pancreatitis | 8 vs 10 cases in SUSTAIN 6; case report of gallstone pancreatitis [3, 5] | 2 years |
| Thyroid cancer | Mixed observational signals; FDA warnings exist [1] | Not studied as primary endpoint |
| Any cancer | Neutral to slightly protective in meta-analyses [1] | 2 years max |
My call: the evidence does not rule out an increased risk of pancreatitis, thyroid tumors, or pancreatic cancer from semaglutide, because no trial was designed to find them and follow-up was too short. Confidence: low for safety on these outcomes.
Sources examined 18
-
GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research
A comprehensive review of clinical and preclinical evidence on GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide, retatrutide) and cancer, showing largely neutral to protective cancer risk signals in humans with obesity/diabetes and tumor-suppressive effects i…
DOI: 10.1172/jci194743 -
Evaluation of Pre-Treatment Assessment of Semaglutide Users: Balancing the Benefits of Weight Loss vs. Potential Health Consequences
A retrospective, single-center study at King Khalid University Hospital, Riyadh, Saudi Arabia, evaluating pretreatment assessments of semaglutide users for obesity, revealing a high burden of comorbidities and substantial gaps in comprehensive pretreatment screening, including m…
DOI: 10.3390/healthcare13151827 -
Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
This case report describes alectinib-induced excessive weight gain in a young ALK+ NSCLC patient that was effectively reduced with semaglutide (GLP-1 receptor agonist), though weight rebounds occurred after discontinuation due to gallstone pancreatitis, highlighting potential, b…
DOI: 10.2147/LCTT.S549011 -
Semaglutide in the Real World: Attitudes of the Population
A cross-sectional Croatian population study assessing awareness of semaglutide (Ozempic) for weight loss, attitudes toward body image, and knowledge of adverse effects, finding that about three-quarters had heard of Ozempic, with women reporting greater appearance-related pressu…
DOI: 10.3390/pharmacy13050128 -
Safety of injectable semaglutide for type 2 diabetes
A narrative safety review of injectable semaglutide for type 2 diabetes, synthesizing safety data from the SUSTAIN programme and related analyses, highlighting overall good safety with gastrointestinal effects, potential renoprotection, a signal for diabetic retinopathy risk lik…
DOI: 10.1080/14740338.2020.1772230 -
Incretin System: Recent Advances in Glucagon Like Peptide-1 and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based therapies, comprising GLP-1 receptor agonists and DPP-4 inhibitors, are reviewed for their mechanisms, efficacy in HbA1c and weight, safety profiles, and key clinical trial evidence in type 2 diabetes.
DOI: 10.3126/jpahs.v1i1.13015 -
Development of a risk prediction model for gastrointestinal adverse events associated with semaglutide administration in patients with type 2 diabetes mellitus
This retrospective single-center cohort study of 215 Chinese patients with type 2 diabetes mellitus found that pre-existing gastrointestinal disorders, alcohol consumption, and concurrent use of α-glucosidase inhibitors were independent risk factors for semaglutide-associated ga…
DOI: 10.3389/fendo.2025.1684395 -
Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial
The SUSTAIN 5 trial demonstrated that semaglutide, when added to basal insulin, significantly improves glycemic control and reduces body weight in patients with type 2 diabetes compared to placebo.
DOI: 10.1210/jc.2018-00070 -
Semaglutide for the Treatment of Type 2 Diabetes Mellitus
This study reviews the efficacy and safety of semaglutide, a GLP-1 receptor agonist, in treating type 2 diabetes mellitus, highlighting its significant reductions in HbA1c and body weight compared to other treatments, along with cardiovascular benefits and potential risks of ret…
DOI: 10.1177/8755122518790925 -
Semaglutide for type 2 diabetes mellitus: A systematic review and meta‐analysis
This systematic review and meta-analysis evaluates the efficacy and safety of semaglutide, a GLP-1 receptor agonist, in reducing HbA1c and body weight in patients with type 2 diabetes mellitus compared to placebo and other antidiabetic agents.
DOI: 10.1111/dom.13361 -
<p>Oral Semaglutide In The Management Of Type 2 Diabetes: A Report On The Evidence To Date</p>
This article reviews the development, pharmacology, and clinical evidence for oral semaglutide in type 2 diabetes, detailing its efficacy (glycemic control and weight loss), cardiovascular safety (non-inferiority with potential mortality benefits in PIONEER-6), safety profile (G…
DOI: 10.2147/DMSO.S229802 -
Semaglutide: Oral GLP-1 Receptor Analogue
Oral semaglutide is presented as a promising, patient-friendly GLP-1 receptor agonist for type 2 diabetes, with HbA1c reductions, weight loss, and favorable cardiovascular safety demonstrated across the PIONEER trial program.
DOI: 10.54136/erwej-0101-10008 -
Long-term Safety Profile of Semaglutide in the Management of Type 2 Diabetes and Obesity
Semaglutide shows overall long-term tolerability in type 2 diabetes and obesity, with dose-dependent gastrointestinal side effects and rare but serious risks like pancreatitis and retinopathy, underscoring the need for extended safety data.
DOI: 10.61173/rvr8p069 -
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
The SUSTAIN 1 trial demonstrated that once-weekly semaglutide monotherapy significantly improves glycaemic control and reduces body weight in treatment-naive patients with type 2 diabetes compared to placebo, with a safety profile similar to existing GLP-1 receptor agonists.
DOI: 10.1016/s2213-8587(17)30013-x -
Semaglutide: Review and Place in Therapy for Adults With Type 2 Diabetes
This review discusses the efficacy and safety of semaglutide, a GLP-1 receptor agonist, in managing type 2 diabetes, highlighting its superior effects on glycemic control and weight loss compared to other treatments, as well as its cardiovascular benefits.
DOI: 10.1016/j.jcjd.2018.05.008 -
Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy
Across the SUSTAIN programme evaluating once-weekly semaglutide for type 2 diabetes, the analysis found no consistent increase in diabetic retinopathy events in most trials, but identified a higher risk of diabetic retinopathy complications (DRC) with semaglutide in high-risk pa…
DOI: 10.1111/dom.13172 -
Semaglutide, a once‐weekly human GLP‐1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel
This study investigates the effect of semaglutide, a once-weekly GLP-1 analog, on the bioavailability of the combined oral contraceptive ethinylestradiol/levonorgestrel in postmenopausal women with type 2 diabetes, finding that semaglutide does not reduce the bioavailability of …
DOI: 10.1002/jcph.443 -
Major clinical outcomes of the action of the co-agonist tirzepatide to liraglutide and semaglutide in the treatment of obesity and type 2 diabetes mellitus: a systematic review
This systematic review evaluates the clinical outcomes of tirzepatide compared to liraglutide and semaglutide in treating obesity and type 2 diabetes mellitus, finding significant weight loss and improved metabolic parameters with tirzepatide.
DOI: 10.54448/ijn25102